LIVE WEBINAR: Thursday, June 29, 2023, 5:00 PM – 6:00 PM Eastern Time

Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer

A CME/MOC-Accredited Live Webinar

Join us on Thursday, June 29th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Terence Friedlander, MD
Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Division of Hematology/Oncology
Zuckerberg San Francisco General Hospital
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Petros Grivas, MD, PhD
Professor, Department of Medicine
Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Seagen Inc, Gilead Sciences Inc, and Merck.

Thursday, June 29, 2023
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Immunotherapy-Based Strategies for Metastatic Urothelial Bladder Cancer (mUBC)
  • MODULE 2: Available Data with, Ongoing Investigation of and Role of Other Novel Strategies for mUBC

Target Audience
This activity is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of metastatic urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recognize how biological and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder cancer (mUBC).
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance therapy after platinum-based chemotherapy for newly diagnosed mUBC, and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds (eg, antibody-drug conjugates, tyrosine kinase inhibitors) with unique mechanisms of action for previously treated, locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
  • Appreciate the biological rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy for UBC, and assess the current and potential roles of these regimens in patient care.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for mUBC.
  • Develop an understanding of the biological rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for mUBC.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Friedlander Advisory Committee: Aadi Bioscience, Astellas, Seagen Inc; Consulting Agreement: Merck; Contracted Research: Bristol Myers Squibb, Roche Laboratories Inc, Seagen Inc, Trishula Therapeutics Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Grivas Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis Inc, Fresenius Kabi AG, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, ImmunityBio, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lucence, Merck KgaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, PureTech Health, QED Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Silverback Therapeutics Inc, Strata Oncology, UroGen Pharma; Contracted Research: Acrivon Therapeutics Inc, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics Inc, Gilead Sciences Inc, GSK, Merck KGaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb.

SURVEY PARTICIPANTSShilpa Gupta, MDAdvisory Committee: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Foundation Medicine, Gilead Sciences Inc, Guardant Health, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Seagen Inc; Consulting Agreements: Bristol Myers Squibb, EMD Serono Inc, Foundation Medicine, Merck; Contracted Research: Bristol Myers Squibb, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Merck, Moderna, Novartis, Pfizer Inc, QED Therapeutics, Roche Laboratories Inc; Speakers Bureau: Bristol Myers Squibb, Gilead Sciences Inc, Seagen Inc; Stock Options/Ownership – Public Company: BioNTech SE, Moderna. Daniel P Petrylak, MDConsulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Monopteros Therapeutics, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Agensys Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Endocyte Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi, Seagen Inc. Elizabeth R Plimack, MD, MSAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, IMV Inc, Janssen Biotech Inc, MEI Pharma Inc, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc. Guru P Sonpavde, MDAdvisory Committee: Astellas, Bicycle Therapeutics, Bristol Myers Squibb, EMD Serono Inc, G1 Therapeutics Inc, Gilead Sciences Inc, IMV Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lucence, Merck, Pfizer Inc, Scholar Rock, Seagen Inc, Tempus; Consulting Agreements: Merck, Servier Pharmaceuticals LLC, Syapse; Contracted Research: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Gilead Sciences Inc, Helsinn Healthcare SA, Jazz Pharmaceuticals Inc, Lucence, Sanofi; Data and Safety Monitoring Board/Committee: Mereo BioPharma; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Gilead Sciences Inc, Janssen Biotech Inc, Natera Inc, Seagen Inc; Nonrelevant Financial Relationship: Informação Brasileira de Oncologia Ltda, Myriad Genetic Laboratories Inc (spouse employment), Onviv, PracticeUpdate, UptoDate, Vial.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, Gilead Sciences Inc, and Merck.